{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:09:53Z","timestamp":1766167793555,"version":"3.48.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03678-0","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T04:11:24Z","timestamp":1754712684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aqueous humor cytokine profile in insufficient responder to aflibercept for neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6182-4343","authenticated-orcid":false,"given":"Ryo","family":"Terao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1762-0797","authenticated-orcid":false,"given":"Ryo","family":"Obata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichiro","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4577-8169","authenticated-orcid":false,"given":"Satoru","family":"Inoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manami","family":"Misawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5331-4730","authenticated-orcid":false,"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"3678_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMcp2102061","volume":"385","author":"RS Apte","year":"2021","unstructured":"Apte RS (2021) Age-related macular degeneration. N Engl J Med 385:539\u2013547. https:\/\/doi.org\/10.1056\/NEJMcp2102061","journal-title":"N Engl J Med"},{"key":"3678_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, Group AS (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444. https:\/\/doi.org\/10.1056\/NEJMoa062655","journal-title":"N Engl J Med"},{"key":"3678_CR3","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U, View, Groups VS (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"3678_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG, Hawk IHS (2020) HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127:72\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017","journal-title":"Ophthalmology"},{"key":"3678_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY, Tenaya IL (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"3678_CR6","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00417-019-04456-2","volume":"257","author":"C Hara","year":"2019","unstructured":"Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, Sakaguchi H, Nishida K (2019) Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol 257:2559\u20132569. https:\/\/doi.org\/10.1007\/s00417-019-04456-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3678_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10384-020-00783-8","volume":"65","author":"Y Tsunekawa","year":"2021","unstructured":"Tsunekawa Y, Kataoka K, Asai K, Ito Y, Terasaki H (2021) Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration. Jpn J Ophthalmol 65:69\u201376. https:\/\/doi.org\/10.1007\/s10384-020-00783-8","journal-title":"Jpn J Ophthalmol"},{"key":"3678_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, Souied EH, Cohen SY, Querques G, Ohno-Matsui K, Boyer D, Gaudric A, Blodi B, Baumal CR, Li X, Coscas GJ, Brucker A, Singerman L, Luthert P, Schmitz-Valckenberg S, Schmidt-Erfurth U, Grossniklaus HE, Wilson DJ, Guymer R, Yannuzzi LA, Chew EY, Csaky K, Mones JM, Pauleikhoff D, Tadayoni R, Fujimoto J (2020) Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology 127:616\u2013636. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004","journal-title":"Ophthalmology"},{"key":"3678_CR9","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s00417-023-06038-9","volume":"261","author":"R Terao","year":"2023","unstructured":"Terao R, Obata R, Okubo A, Aoki S, Azuma K, Ahmed T, Inoda S, Hashimoto Y, Takahashi R, Yoshida H, Misawa M, Takahashi H, Takahashi H (2023) Cytokine profiles in the aqueous humor following brolucizumab administration for exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 261:2465\u20132476. https:\/\/doi.org\/10.1007\/s00417-023-06038-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3678_CR10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00417-021-05445-0","volume":"260","author":"S Inoda","year":"2022","unstructured":"Inoda S, Takahashi H, Inoue Y, Tan X, Tampo H, Arai Y, Yanagi Y, Kawashima H (2022) Cytokine profiles of macular neovascularization in the elderly based on a classification from a pachychoroid\/drusen perspective. Graefes Arch Clin Exp Ophthalmol 260:747\u2013758. https:\/\/doi.org\/10.1007\/s00417-021-05445-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3678_CR11","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1007\/s12325-020-01298-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Lanzetta P, Korobelnik JF, Wojciechowski P, Taieb V, Deschaseaux C, Janer D, Tuckmantel C (2020) Efficacy and treatment burden of intravitreal aflibercept versus intravitreal ranibizumab treat-and-extend regimens at 2 years: network meta-analysis incorporating individual patient data meta-regression and matching-adjusted indirect comparison. Adv Ther 37:2184\u20132198. https:\/\/doi.org\/10.1007\/s12325-020-01298-x","journal-title":"Adv Ther"},{"key":"3678_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155145","author":"M Kishi","year":"2023","unstructured":"Kishi M, Miki A, Kamimura A, Okuda M, Matsumiya W, Imai H, Kusuhara S, Nakamura M (2023) Short-term outcomes of faricimab treatment in aflibercept-refractory eyes with neovascular age-related macular degeneration. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12155145","journal-title":"J Clin Med"},{"key":"3678_CR13","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1111\/j.1755-3768.2012.02414.x","volume":"90","author":"JB Jonas","year":"2012","unstructured":"Jonas JB, Tao Y, Neumaier M, Findeisen P (2012) Cytokine concentration in aqueous humour of eyes with exudative age-related macular degeneration. Acta Ophthalmol 90:e381-388. https:\/\/doi.org\/10.1111\/j.1755-3768.2012.02414.x","journal-title":"Acta Ophthalmol"},{"key":"3678_CR14","doi-asserted-by":"publisher","first-page":"45081","DOI":"10.1038\/srep45081","volume":"7","author":"DS Ng","year":"2017","unstructured":"Ng DS, Yip YW, Bakthavatsalam M, Chen LJ, Ng TK, Lai TY, Pang CP, Brelen ME (2017) Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation. Sci Rep 7:45081. https:\/\/doi.org\/10.1038\/srep45081","journal-title":"Sci Rep"},{"key":"3678_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/IAE.0000000000001554","volume":"38","author":"JH Kim","year":"2018","unstructured":"Kim JH, Shin JP, Kim IT, Park DH (2018) Angiopoietin-like 4 correlates with response to intravitreal ranibizumab injections in neovascular age-related macular degeneration. Retina 38:523\u2013530. https:\/\/doi.org\/10.1097\/IAE.0000000000001554","journal-title":"Retina"},{"key":"3678_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/bjo.2011.203893","volume":"96","author":"MS Eghoj","year":"2012","unstructured":"Eghoj MS, Sorensen TL (2012) Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 96:21\u201323. https:\/\/doi.org\/10.1136\/bjo.2011.203893","journal-title":"Br J Ophthalmol"},{"key":"3678_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2011-301236","volume":"96","author":"S Binder","year":"2012","unstructured":"Binder S (2012) Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 96:1\u20132. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-301236","journal-title":"Br J Ophthalmol"},{"key":"3678_CR18","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.2147\/OPTH.S171636","volume":"12","author":"P Pongsachareonnont","year":"2018","unstructured":"Pongsachareonnont P, Mak MYK, Hurst CP, Lam WC (2018) Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment. Clin Ophthalmol 12:1877\u20131885. https:\/\/doi.org\/10.2147\/OPTH.S171636","journal-title":"Clin Ophthalmol"},{"key":"3678_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000478705","volume":"58","author":"R Motohashi","year":"2017","unstructured":"Motohashi R, Noma H, Yasuda K, Kotake O, Goto H, Shimura M (2017) Dynamics of inflammatory factors in aqueous humor during ranibizumab or aflibercept treatment for age-related macular degeneration. Ophthalmic Res 58:209\u2013216. https:\/\/doi.org\/10.1159\/000478705","journal-title":"Ophthalmic Res"},{"key":"3678_CR20","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/s41598-018-19594-6","volume":"8","author":"T Sato","year":"2018","unstructured":"Sato T, Takeuchi M, Karasawa Y, Enoki T, Ito M (2018) Intraocular inflammatory cytokines in patients with neovascular age-related macular degeneration before and after initiation of intravitreal injection of anti-VEGF inhibitor. Sci Rep 8:1098. https:\/\/doi.org\/10.1038\/s41598-018-19594-6","journal-title":"Sci Rep"},{"key":"3678_CR21","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.thromres.2012.06.023","volume":"130","author":"B Van De Craen","year":"2012","unstructured":"Van De Craen B, Declerck PJ, Gils A (2012) The biochemistry, physiology and pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb Res 130:576\u2013585. https:\/\/doi.org\/10.1016\/j.thromres.2012.06.023","journal-title":"Thromb Res"},{"key":"3678_CR22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1096\/fj.00-0393com","volume":"15","author":"V Lambert","year":"2001","unstructured":"Lambert V, Munaut C, Noel A, Frankenne F, Bajou K, Gerard R, Carmeliet P, Defresne MP, Foidart JM, Rakic JM (2001) Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J 15:1021\u20131027. https:\/\/doi.org\/10.1096\/fj.00-0393com","journal-title":"FASEB J"},{"key":"3678_CR23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.exer.2008.11.036","volume":"88","author":"R Fuchshofer","year":"2009","unstructured":"Fuchshofer R, Yu AL, Teng HH, Strauss R, Kampik A, Welge-Lussen U (2009) Hypoxia\/reoxygenation induces CTGF and PAI-1 in cultured human retinal pigment epithelium cells. Exp Eye Res 88:889\u2013899. https:\/\/doi.org\/10.1016\/j.exer.2008.11.036","journal-title":"Exp Eye Res"},{"key":"3678_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.594087","volume":"11","author":"I Mantel","year":"2020","unstructured":"Mantel I, Borgo A, Guidotti J, Forestier E, Kirsch O, Derradji Y, Waridel P, Burdet F, Mehl F, Schweizer C, Roduit R (2020) Molecular biomarkers of neovascular age-related macular degeneration with incomplete response to anti-vascular endothelial growth factor treatment. Front Pharmacol 11:594087. https:\/\/doi.org\/10.3389\/fphar.2020.594087","journal-title":"Front Pharmacol"},{"key":"3678_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/iovs.65.11.15","volume":"65","author":"T Todoroki","year":"2024","unstructured":"Todoroki T, Takeuchi J, Ota H, Nakano Y, Sajiki AF, Nakamura K, Kaneko H, Nishiguchi KM (2024) Aqueous humor cytokine analysis in age-related macular degeneration after switching from aflibercept to faricimab. Invest Ophthalmol Vis Sci 65:15. https:\/\/doi.org\/10.1167\/iovs.65.11.15","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Pt 3","key":"3678_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1042\/bj3460603","volume":"346","author":"I Kim","year":"2000","unstructured":"Kim I, Kim HG, Kim H, Kim HH, Park SK, Uhm CS, Lee ZH, Koh GY (2000) Hepatic expression, synthesis and secretion of a novel fibrinogen\/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J 346(Pt 3):603\u2013610","journal-title":"Biochem J"},{"key":"3678_CR27","doi-asserted-by":"publisher","first-page":"36841","DOI":"10.1074\/jbc.M111.220061","volume":"286","author":"EG Perdiguero","year":"2011","unstructured":"Perdiguero EG, Galaup A, Durand M, Teillon J, Philippe J, Valenzuela DM, Murphy AJ, Yancopoulos GD, Thurston G, Germain S (2011) Alteration of developmental and pathological retinal angiogenesis in angptl4-deficient mice. J Biol Chem 286:36841\u201336851. https:\/\/doi.org\/10.1074\/jbc.M111.220061","journal-title":"J Biol Chem"},{"key":"3678_CR28","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1111\/aos.12097","volume":"91","author":"H Yokouchi","year":"2013","unstructured":"Yokouchi H, Eto K, Nishimura W, Takeda N, Kaburagi Y, Yamamoto S, Yasuda K (2013) Angiopoietin-like protein 4 (ANGPTL4) is induced by high glucose in retinal pigment epithelial cells and exhibits potent angiogenic activity on retinal endothelial cells. Acta Ophthalmol 91:e289-297. https:\/\/doi.org\/10.1111\/aos.12097","journal-title":"Acta Ophthalmol"},{"key":"3678_CR29","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/nm884","volume":"9","author":"M Autiero","year":"2003","unstructured":"Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr-Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, Van Hummelen P, Dehio C, Hicklin DJ, Persico G, Herbert JM, Communi D, Shibuya M, Collen D, Conway EM, Carmeliet P (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9:936\u2013943. https:\/\/doi.org\/10.1038\/nm884","journal-title":"Nat Med"},{"key":"3678_CR30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.survophthal.2024.07.009","volume":"69","author":"L Schloesser","year":"2024","unstructured":"Schloesser L, Klose SM, Mauschitz MM, Abdullah Z, Finger RP (2024) The role of immune modulators in age-related macular degeneration. Surv Ophthalmol 69:851\u2013869. https:\/\/doi.org\/10.1016\/j.survophthal.2024.07.009","journal-title":"Surv Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03678-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03678-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03678-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:05:57Z","timestamp":1766167557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03678-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3678"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03678-0","relation":{},"ISSN":["1573-2630"],"issn-type":[{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves human participants and was approved by the Institutional Board of Jichi Medical University Hospital (Ethics Approval Number: CU22-R003).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Ryo Terao declares lecturer\u2019s fees from Bayer, Santen, Kowa, and Chugai, and research grant from Japan Medical Association, Kowa Life Science Foundation, and ARVO Foundation for Eye Research. Ryo Obata has received honoraria for speaking and consulting from Santen, Bayer, Novartis, Chugai, and Senju. Satoru Inoda declares lecturer\u2019s fees from Kowa, Santen, Novartis, Bayer, Senju, Chugai, and DeepEyeVision, Inc., and grants from HOYA and Novartis outside this work. Hidenori Takahashi has received research grants form Kyowa Kirin, Novartis, Bayer, Linical Inc., consultant fee from Beringer, and honorarium from Santen, Kowa, Beryer, Viatris, Senju, MSD, Chugai, HOYA, Novartis, and Nikon. The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"326"}}